- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07567092
A Study of VIRTUGUIDE System and DePuy Synthes Lapidus Implant in Participants Undergoing Lapidus Procedure
2026년 8월 27일 업데이트: DePuy Synthes Products, Inc.
VIRTUGUIDE™ SYSTEM REGISTRY
The purpose of this study is to assess the surgeon experience and surgery outcomes in participants undergoing index Lapidus procedure for the correction of hallux valgus (a foot deformity where the big toe angles outward towards the other toes, causing a painful bony bump at the base of the big toe joint) using the VIRTUGUIDE System and compatible DePuy Synthes Lapidus implants.
연구 개요
상태
모병
정황
연구 유형
관찰
등록 (추정된)
100
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
- 이름: Marcie Maichle
- 전화번호: 443-987-0665
- 이메일: MMaichle@ITS.JNJ.com
연구 연락처 백업
- 이름: Priyamvada Devineni
- 이메일: pdevinen@its.jnj.com
연구 장소
-
-
Virginia
-
Virginia Beach, Virginia, 미국, 23462
- 모병
- Atlantic Orthopaedic Specialists
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
샘플링 방법
비확률 샘플
연구 인구
The study population will include adults who will undergo surgical treatment for the correction of hallux valgus via Lapidus procedure using the VIRTUGUIDE System and will receive a compatible DePuy Synthes Lapidus implant.
설명
Inclusion criteria:
- Participants, both male and female, >= 22 years old at the time of consent
- Participants undergoing a primary Lapidus procedure for the correction of hallux valgus using the VIRTUGUIDE System (software + instruments) and who receive a compatible DePuy Synthes Lapidus implant
- Participants must be able to read and understand questions and responses in an available translated language for patient reported outcomes (PROMs)
- All primary Lapidus fixation implants are used on-label according to the implant IFU/FDA cleared labeling
- Participants who can speak, read, and comprehend the Institutional Review Board approved Informed Consent Document and are willing and able to provide informed patient consent for participation and have authorized the transfer of his/her information to DePuy Synthes
Exclusion criteria:
- Participation in any other medical device or medicinal product study within the previous month. Participation in observational studies is allowed
- In the opinion of the Principal Investigator, the subject is unable to comply with the requirements of the registry
- Participant has known allergies to implant components
- Participant presenting for a revision of a Lapidus procedure
- Participant has existing hardware in the operative joint
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
VIRTUGUIDE System and Compatible DePuy Synthes Lapidus Implant(s)
Participants with hallux valgus undergoing index Lapidus procedure using the VIRTUGUIDE System and compatible DePuy Synthes Lapidus implant(s) will be enrolled in the study.
All participants will be followed up as per the surgeon's standard of care for up to 12 months after the surgery.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Radiographic Documentation of Fusion/Healing Status
기간: Up to 12 months post-procedure
|
Evaluation of healing, that is, healing will be a combination of radiographic and clinical assessment.
Healing (fusion) will be considered achieved based on surgeon interpretation of radiographic images, lack of clinical motion and no pain at the fused site indicative of failed fusion.
Imaging, whether X-ray or computed tomography (CT) collected per standard of care (SOC), utilized for radiographic assessment will be collected.
|
Up to 12 months post-procedure
|
|
Patient Reported Outcome Measures (PROM): Manchester Oxford Foot Questionnaire (Quality of Life Index) Scores
기간: Up to 12 months post-procedure
|
The Manchester Oxford Foot Questionnaire (MOxFQ) with three domains (walking/standing, pain, and social interaction) is a standardized instrument developed and validated specifically for hallux valgus (bunions) corrective surgery.
It is widely regarded as the gold standard for content and construct validity.
It is designed for self (participant) completion and consists of sixteen (16) questions all of which are scored on a five (5) item Likert scale.
The scores for each domain range from 0-100, with 100 representing the worst condition.
|
Up to 12 months post-procedure
|
|
PROM: Numeric Pain Rating Scale Scores
기간: Up to 12 months post-procedure
|
The Numeric Pain Rating Scale is a three (3) question self-administered PROM with a 10-point one-dimensional line anchored on either end by verbal descriptors ranging from "no pain" to "worst imaginable pain".
The higher score indicates greater pain intensity.
The three questions ask the participant to indicate the intensity of current, best, and worst pain levels over the past 24 hours.
|
Up to 12 months post-procedure
|
|
Number of Participants Reporting any Perioperative Adverse Event (AE)
기간: Up to 12 months post-procedure
|
An AE is any untoward medical occurrence (sign, symptom, or disease) in a participant that is deemed at least possibly related to the DePuy Synthes registry device, or any adjunctive implant device used during the index procedure.
|
Up to 12 months post-procedure
|
|
Number of Participants with AEs Related to Device/Procedure
기간: Up to 12 months post-procedure
|
An AE is any untoward medical occurrence (sign, symptom, or disease) in a participant that is deemed at least possibly related to the DePuy Synthes registry device, or any adjunctive implant device used during the index procedure.
The determination of whether the AE is related to the device and/or procedure will be based upon whether a causal relationship between the device and/or procedure and the AE is at least a reasonable possibility, i.e., the relationship cannot be ruled out.
A causal relationship cannot be ruled out if, in the medical judgment of the Investigator, the effect follows a reasonable temporal association with the use of the device and/or is confirmed by the improvement of the effect upon discontinuation of the clinical use of the device, and/or the effect is not reasonably explained by the participant's clinical state.
|
Up to 12 months post-procedure
|
|
Number of Participants with Serious Adverse Events (SAEs)
기간: Up to 12 months post-procedure
|
SAEs are AEs defined as having one or more of the following outcomes: death, serious deterioration in the health of the subject that has resulted in a. life-threatening illness or injury b. permanent impairment of a body structure or a body function c. hospitalization or prolongation of existing hospitalization d. medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function e. chronic disease and Fetal distress, fetal death or a congenital physical or mental impairment or birth defect.
|
Up to 12 months post-procedure
|
|
Number of Participants Reporting Device Deficiency
기간: Up to 12 months post-procedure
|
Device deficiencies include malfunctions, use errors, and inadequate labeling.
Device malfunctions are failures of the device to perform as intended and can be defined as issues with software (VIRTUGUIDE Pre-Planning Software), any breakage, malposition, migration, and/or loosening of the device.
|
Up to 12 months post-procedure
|
|
Number of Participants who Underwent Revision
기간: Up to 12 months post-procedure
|
Revision is defined as surgery following the index Lapidus procedure that involves adjustment, modification, removal, or replacement of the implanted device.
Surgeries involving adjunctive implants at the first metatarsal-cuneiform joint are considered as a revision.
|
Up to 12 months post-procedure
|
|
Number of Participants who Underwent Reoperation
기간: Up to 12 months post-procedure
|
Reoperation is defined as any subsequent surgical procedure performed following the index surgery that does not involve adjustment, modification, removal, or replacement of the primary Lapidus implant(s), nor the addition of adjunctive fixation at the first metatarsal-cuneiform joint.
|
Up to 12 months post-procedure
|
|
Number of Participants Reporting Recurrence
기간: Up to 12 months post-procedure
|
Radiographic recurrence will be considered to have occurred in those subjects with correction if both of the following criteria are met: Intermetatarsal Angle (IMA) of greater than (>)12 degree and Hallux Valgus Angle (HVA) > 15 degree.
|
Up to 12 months post-procedure
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
- 연구 책임자: DePuy Synthes Products, Inc. Clinical Trial, DePuy Synthes Products, Inc.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2026년 7월 7일
기본 완료 (추정된)
2028년 5월 15일
연구 완료 (추정된)
2028년 5월 15일
연구 등록 날짜
최초 제출
2026년 4월 28일
QC 기준을 충족하는 최초 제출
2026년 4월 28일
처음 게시됨 (실제)
2026년 5월 5일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 8월 28일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 8월 27일
마지막으로 확인됨
2026년 8월 1일
추가 정보
이 연구와 관련된 용어
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
예
IPD 계획 설명
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .